학술논문
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Document Type
Article
Author
Choueiri, T.K.; McGregor, B.; Eto, M.; Motzer, R.; De Giorgi, U.; Buchler, T.; Basappa, N.S.; Méndez-Vidal, M.J.; Tjulandin, S.; Hoon Park, S.; Melichar, B.; Hutson, T.; Alemany, C.; Powles, T.; Grünwald, V.; Alekseev, B.; Rha, S.Y.; Kopyltsov, E.; Kapoor, A.; Alonso Gordoa, T.; Goh, J.C.; Staehler, M.; Merchan, J.R.; Xie, R.; Mody, K.; McKenzie, J.; Perini, R.F.; Porta, C.G.
Source
In: The Lancet Oncology . (The Lancet Oncology, March 2023, 24(3):228-238)
Subject
Language
English
ISSN
14745488
14702045
14702045